on VALBIOTIS (EPA:ALVAL)
Valbiotis welcomes the law on cardiovascular prevention
Valbiotis, a French laboratory specializing in cardiometabolic health, applauds the adoption of the law on cardiovascular prevention by Parliament. This legislation strengthens awareness and screening for cardiovascular and neurovascular diseases, incorporating blood pressure monitoring and the role of pharmacists. It also promotes prevention initiatives in the workplace.
The law aligns with Valbiotis' commitment to developing solutions to prevent cardiometabolic imbalances before they occur. The company offers a range of clinically tested products and training for healthcare professionals. Valbiotis is thus positioning itself as a key player in public health prevention.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VALBIOTIS news